156 related articles for article (PubMed ID: 12084892)
1. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP.
Brannagan TH; Pradhan A; Heiman-Patterson T; Winkelman AC; Styler MJ; Topolsky DL; Crilley PA; Schwartzman RJ; Brodsky I; Gladstone DE
Neurology; 2002 Jun; 58(12):1856-8. PubMed ID: 12084892
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in systemic lupus erythematosus (SLE) with oral cyclophosphamide.
Jasmin R; Sockalingam S; Shahrizaila N; Cheah TE; Zain AA; Goh KJ
Lupus; 2012 Sep; 21(10):1119-23. PubMed ID: 22433918
[TBL] [Abstract][Full Text] [Related]
3. Successful repeated treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP.
Axelson HW; Oberg G; Askmark H
J Neurol Neurosurg Psychiatry; 2008 May; 79(5):612-4. PubMed ID: 18408093
[No Abstract] [Full Text] [Related]
4. High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy.
Gladstone DE; Prestrud AA; Brannagan TH
J Peripher Nerv Syst; 2005 Mar; 10(1):11-6. PubMed ID: 15703014
[TBL] [Abstract][Full Text] [Related]
5. Distal acquired demyelinating symmetric polyneuropathy progressing to classic chronic inflammatory demyelinating polyneuropathy and response to fludarabine and cyclophosphamide.
Leitch MM; Sherman WH; Brannagan TH
Muscle Nerve; 2013 Feb; 47(2):292-6. PubMed ID: 23168526
[TBL] [Abstract][Full Text] [Related]
6. High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients.
Gladstone DE; Golightly MG; Brannagan TH
J Neuroimmunol; 2007 Oct; 190(1-2):121-6. PubMed ID: 17854912
[TBL] [Abstract][Full Text] [Related]
7. Chronic inflammatory demyelinating polyradiculoneuropathy in solid organ transplant recipients: a prospective study.
Echaniz-Laguna A; de Séze J; Chanson JB
J Neurol Neurosurg Psychiatry; 2012 Jul; 83(7):699-705. PubMed ID: 22577230
[TBL] [Abstract][Full Text] [Related]
8. Chronic inflammatory demyelinating polyradiculoneuropathy: long-term course and treatment of 60 patients.
Sghirlanzoni A; Solari A; Ciano C; Mariotti C; Fallica E; Pareyson D
Neurol Sci; 2000 Feb; 21(1):31-7. PubMed ID: 10938200
[TBL] [Abstract][Full Text] [Related]
9. [Treatment with interferon-alpha 2a in a patient with chronic inflammatory demyelinating polyneuropathy].
Ueda M; Ota K; Takeuchi M; Tsutsumi Y; Iwata M
Rinsho Shinkeigaku; 2000 Feb; 40(2):155-9. PubMed ID: 10835937
[TBL] [Abstract][Full Text] [Related]
10. Severe refractory CIDP: a case series of 10 patients treated with bortezomib.
Pitarokoili K; Yoon MS; Kröger I; Reinacher-Schick A; Gold R; Schneider-Gold C
J Neurol; 2017 Sep; 264(9):2010-2020. PubMed ID: 28836002
[TBL] [Abstract][Full Text] [Related]
11. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin.
Cirillo G; Todisco V; Tedeschi G
Clin Neurophysiol; 2018 May; 129(5):967-973. PubMed ID: 29554579
[TBL] [Abstract][Full Text] [Related]
12. CIDP cured by allogeneic hematopoietic stem cell transplantation.
Reményi P; Masszi T; Borbényi Z; Soós J; Siklós L; Engelhardt JI
Eur J Neurol; 2007 Aug; 14(8):e1-2. PubMed ID: 17661987
[No Abstract] [Full Text] [Related]
13. Response to methotrexate in a chronic inflammatory demyelinating polyradiculoneuropathy patient.
Díaz-Manera J; Rojas-García R; Gallardo E; Illa I
Muscle Nerve; 2009 Mar; 39(3):386-8. PubMed ID: 19208395
[TBL] [Abstract][Full Text] [Related]
14. Outcome in chronic inflammatory demyelinating polyneuropathy from a Malaysian centre over sixteen years.
Hiew FL; Ong JJ; Viswanathan S; Puvanarajah S
J Clin Neurosci; 2018 Apr; 50():203-207. PubMed ID: 29398193
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis.
Cocito D; Grimaldi S; Paolasso I; Falcone Y; Antonini G; Benedetti L; Briani C; Fazio R; Jann S; Matà S; Sabatelli M; Nobile-Orazio E;
Eur J Neurol; 2011 Dec; 18(12):1417-21. PubMed ID: 21819489
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in refractory chronic inflammatory demyelinating polyneuropathy.
Muley SA; Jacobsen B; Parry G; Usman U; Ortega E; Walk D; Allen J; Pasnoor M; Varon M; Dimachkie MM
Muscle Nerve; 2020 May; 61(5):575-579. PubMed ID: 31922613
[TBL] [Abstract][Full Text] [Related]
17. Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies.
Dalakas MC
J Peripher Nerv Syst; 2012 May; 17 Suppl 2():34-9. PubMed ID: 22548621
[TBL] [Abstract][Full Text] [Related]
18. CIDP variants in diabetes: measuring treatment response with a small nerve fiber test.
Névoret ML; Vinik AI
J Diabetes Complications; 2015 Mar; 29(2):313-7. PubMed ID: 25466645
[TBL] [Abstract][Full Text] [Related]
19. Different electrophysiological profiles and treatment response in 'typical' and 'atypical' chronic inflammatory demyelinating polyneuropathy.
Kuwabara S; Isose S; Mori M; Mitsuma S; Sawai S; Beppu M; Sekiguchi Y; Misawa S
J Neurol Neurosurg Psychiatry; 2015 Oct; 86(10):1054-9. PubMed ID: 25424435
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine in the Treatment of Refractory Chronic Inflammatory Demyelinating Neuropathies.
Leitch MM; Sherman WH; Brannagan TH
J Clin Neuromuscul Dis; 2015 Sep; 17(1):1-5. PubMed ID: 26301372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
